Oregon Health & Science University (OHSU) researchers were searching a genetic database for compounds that could suppress the expression of genes previously linked to heavy alcohol use. They put apremilast to the test in two animal models with a genetic risk of binge drinking, as well as in mice from other labs. In each case, apremilast reduced alcohol consumption by increasing activity in the nucleus accumbens, the brain region involved in controlling alcohol intake. Scripps Research Institute then assessed 51 patients over 11 days of treatment and discovered that trial participants’ alcohol consumption was reduced from an average of five drinks per day to two.